Journal article
Viral vectors as vaccine platforms: deployment in sight.
- Abstract:
- A little more than a decade after the explosion of research into recombinant live-attenuated or replication-deficient viruses as vaccine platforms, many viral vector-based vaccines have been licensed for animals. Progress has been slower for humans but 2011 will see the licensure of the first viral-vectored vaccine for humans, against Japanese Encephalitis. In addition a vaccine with a viral-vectored component showed efficacy against HIV infection in humans. Viral-based vaccines have an excellent safety profile but must deal with the potential problem of pre-existing anti-vector immunity. Recent successes reflect diverse improvements such as development of new adenovirus serotypes and better prime-boost approaches, suggesting that many viral vectors are approaching their final years as vaccine 'candidates' rather than vaccines.
- Publication status:
- Published
Actions
Access Document
- Publisher copy:
- 10.1016/j.coi.2011.03.006
Authors
- Journal:
- Current opinion in immunology More from this journal
- Volume:
- 23
- Issue:
- 3
- Pages:
- 377-382
- Publication date:
- 2011-06-01
- DOI:
- EISSN:
-
1879-0372
- ISSN:
-
0952-7915
- Language:
-
English
- Keywords:
- Pubs id:
-
pubs:134990
- UUID:
-
uuid:9c61cc4e-38d7-48c5-b388-4968fb5a7085
- Local pid:
-
pubs:134990
- Source identifiers:
-
134990
- Deposit date:
-
2012-12-19
- ARK identifier:
Terms of use
- Copyright date:
- 2011
If you are the owner of this record, you can report an update to it here: Report update to this record